Gene Modification Company Transposagen Receives $4.3M in Grants, Investments | GenomeWeb

NEW YORK (GenomeWeb News) – Gene modification firm Transposagen Biopharmaceuticals said on Friday that it received $4.3 million in grants and investments to further develop its DNA modification technology.

The Lexington, Ky.-based firm said that it received a Small Business Innovation Research grant of almost $2.0 million from the National Institutes of Health's Office of the Director, and a $1.0 million grant from the Kentucky Cabinet for Economic Development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic mechanism through which some cancers evade the immune system, and more.

The Wall Street Journal reports that Walgreens didn't fully vet Theranos before entering partnership.

Jeremy Berg is to be the next editor in chief of Science magazine.

Regeneron Pharmaceuticals is to be the new sponsor of the prestigious high school Science Talent Search competition, according to the New York Times.